Expansion Plan Annouced at DCAT Including Oligonucleotide

We thank DCAT for the opportunity to share our capability and capacity expansion plan at the Member Company Announcement Forum during DCAT week last month. We hope our investment across API and drug product for small molecule, oligonucleotide, peptide, and their conjugates will enable more novel medicines to the global market faster.

Read the announcement summary here: https://www.dcatvci.org/supplier-news/wuxi-sta-outlines-major-expansion-plans/

To view more news and webinars, please follow our LinkedIn page.